Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis.  The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients.  In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

David Brand, President and CEO of Tarsa noted, "These are promising developments as we advance our once-daily oral calcitonin tablet that has the potential to offer patients the proven safety and efficacy of calcitonin with the significant advantage of easier administration and the potential for enhanced long-term compliance.  We are delighted that enrollment in the ORACAL trial has proceeded so well and that the DMC has confirmed that there are no safety issues that prevent us from continuing the trial as planned.  We look forward to reporting data from the complete Phase III study next year."

Calcitonin is approved for the treatment of postmenopausal women with osteoporosis, but its use has been limited by the fact that it is currently available only in intranasal and injectable forms.  Tarsa's oral calcitonin product has been shown in prior clinical studies to deliver the desired blood levels of calcitonin and reduce levels of bone resorption biomarkers.  It has the potential to offer a new therapeutic option for osteoporosis patients as the first FDA-approved and commercially available oral formulation of calcitonin.

Dr. David Krause, Chief Medical Officer of Tarsa, commented, "We are hearing considerable interest from health professionals who would like access to the treatment option of an osteoporosis product that offers calcitonin's record of safety and efficacy along with the ease-of-use of an oral product, thereby enhancing patient acceptance and compliance.  In addition, continuing concerns about potential long-term safety issues with other popular classes of osteoporosis drugs highlight the need for additional choices for osteoporosis patients and their healthcare providers."